R&D On CB1s as an alternative to GLP-1s, with Punit Dhillon In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.
Digital How integrated patient experience platforms are revolutionis... AI-powered integrated platforms offer an elemental shift in the way that clinical trials are conducted.
News Real-world trial of Lilly's tirzepatide starts in UK A real-world study exploring the long-term effects of Eli Lilly's weight-loss therapy tirzepatide in primary care settings has started in the UK.
News Novo Nordisk files Wegovy product that claimed rapid voucher Novo Nordisk is using its recently awarded FDA priority voucher on a high-strength version of its obesity drug Wegovy.
News Data sets up phase 3 trials for Novo's amycretin in diabetes Novo Nordisk has decided to move its amycretin into pivotal trials in type 2 diabetes after a phase 2 readout.
News Innovent files high-dose mazdutide for obesity in China Innovent has filed a new high-strength version of its weight-loss drug mazdutide in China, aiming to help people with severe obesity.
News Akiram, ITM sign Lutetium-177 supply agreement Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
